Meclocycline
(Synonyms: 氯甲烯土霉素) 目录号 : GC44150A tetracycline antibiotic
Cas No.:2013-58-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Meclocycline is a tetracycline antibiotic. It has broad antimicrobial activity in vitro, including growth inhibition of the bacterium S. epidermidis when used at a concentration of 0.8 µg/ml. Meclocycline inhibits lactate dehydrogenase (LDH) release and cell toxicity induced by expression of htt-N63-148Q, a mutant form of the huntingtin gene, without altering htt-N63-148Q protein levels in PC12 cells.
| Cas No. | 2013-58-3 | SDF | |
| 别名 | 氯甲烯土霉素 | ||
| Canonical SMILES | OC([C@@](C(C(C(N)=O)=C(O)[C@H]1N(C)C)=O)(O)[C@@]1([H])[C@H]2O)=C([C@@]2([H])C3=C)C(C4=C3C(Cl)=CC=C4O)=O | ||
| 分子式 | C22H21ClN2O8 | 分子量 | 476.9 |
| 溶解度 | DMF: soluble,DMSO: soluble,Ethanol: soluble,Methanol: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0969 mL | 10.4844 mL | 20.9688 mL |
| 5 mM | 0.4194 mL | 2.0969 mL | 4.1938 mL |
| 10 mM | 0.2097 mL | 1.0484 mL | 2.0969 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Topical Meclocycline sulfosalicylate, benzoyl peroxide, and a combination of the two in the treatment of acne vulgaris
Acta Derm Venereol 1991;71(2):175-8.PMID:1675534DOI:10.2340/0001555571175178.
One hundred and six patients with acne vulgaris of the face were treated for 10 weeks with either topical Meclocycline sulfosalicylate, topical benzoyl peroxide or both preparations. A randomized, double-blind parallel group study was used. Benzoyl peroxide proved more effective than Meclocycline in reducing acne lesion counts, while local side effects were more common in the benzoyl peroxide-treated patients. The combined treatment was of intermediate efficacy with fewer local side effects.
Determination of Meclocycline, a tetracycline analogue, in cream formulations by liquid chromatography
J Pharm Sci 1984 Nov;73(11):1650-1.PMID:6520775DOI:10.1002/jps.2600731143.
A rapid and sensitive high-performance liquid chromatographic quantitation of Meclocycline (I) in a cream formulation is described. The acidified methanolic extract of the sample was diluted with mobile phase and analyzed on a reverse-phase column by using a mobile phase consisting of EDTA buffer (pH 6.6)-tetrahydrofuran (85:15 v/v). The method gave linear, quantitative, and reproducible results with a detection limit of 0.4 ppm for Meclocycline.
13C-NMR spectroscopy of three tetracycline antibiotics: minocycline hydrochloride, Meclocycline, and rolitetracycline
J Pharm Sci 1980 Feb;69(2):229-30.PMID:7359336DOI:10.1002/jps.2600690236.
13C-NMR data and spectral assignments are presented for tetracycline antibiotics minocycline hydrochloride, Meclocycline, and rolitetracycline.
Meclocycline sulfosalicylate. Topical antibiotic agent for the treatment of acne vulgaris
Cutis 1981 Feb;27(2):203-4, 208-10.PMID:6452987doi
Meclocycline sulfosalicylate is a broad spectrum antimicrobial agent that was synthesized in 1960 and has been marketed abroad for several years. Clinical studies in the United States to date involve 351 patients. The results of a regimen using topically applied Meclocycline sulfosalicylate, 1 percent, as the sole treatment are examined. Overall 82 percent of the patients treated with the active preparation experienced clinical improvement in a twice daily application regimen. Excellent of good results were obtained in 62.3 percent of patients treated with Meclocycline sulfosalicylate cream as compared with 27.5 percent of those treated with the cream vehicle alone. The median percent reduction in the number of inflammatory lesions of acne among patients treated for 11 weeks was 57.1 percent. Rapid response was noted at week 5, with nearly a 50 percent median reduction in papules and pustules. The low incidence of local adverse effects was noteworthy. Only one case of contact dermatitis possibly related to treatment was reported among the patients studied.
[Double-blind group comparison of topical Meclocycline, erythromycin and placebo in the treatment of papulo-pustulosa acne]
Z Hautkr 1984 Dec 1;59(23):1623-34.PMID:6240840doi
Ten institutions participated in a controlled clinical trial in order to evaluate the efficacy of topical Meclocycline and erythromycin in comparison to placebo with regard to papulopustular acne. Both drugs had been incorporated in the same galenic formulation that served as placebo. The vehicle employed in this study guaranteed equally favorable drug relies for both preparations. At the end of the trial, 419 patients could be evaluated for efficacy. As impartial criterion for evaluation, the number of inflammatory lesions on the right side of the face was counted before and after three months of treatment. In addition, we recorded the patients' and physicians' overall judgment at the end of the study. As compared with placebo, Meclocycline as well as erythromycin brought about statistically significant improvement already after two months of treatment. After three months, the results were statistically very highly significant (p less than 0.001). At any time of the study, there could not be demonstrated any difference between the two groups treated with Meclocycline and erythromycin.